Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases

British Journal of Dermatology

Volumn 157, Issue 3, 2007, Pages 531-539

  Mourmouras, V ^a   Fimiani, M ^a   Rubegni, P ^a   Epistolato, M C ^a   Malagnino, V ^a   Cardone, C ^a   Cosci, E ^a   Nisi, M C De ^a   Miracco, C ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

CD4+CD25+FOXP3+ regulatory T cells; Cutaneous melanocytic lesions; Immunohistochemistry; Tumour infiltrating lymphocytes

Indexed keywords

ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DYSPLASTIC NEVUS; GROWTH CURVE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STATISTICAL SIGNIFICANCE; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD4; FEMALE; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; NEVUS, PIGMENTED; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL;

EID: 34547896612     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08057.x     Document Type: Article

References (51)

1. Linehan DC, Goedegebuure PS. CD25+CD4+ regulatory T-cells in cancer. Immunol Res 2005 32 : 155 68.
2. Banham AH, Powrie FM, Suri-Payer E. FOXP3+ regulatory T cells: current controversies and future perspectives. Eur J Immunol 2006 36 : 2832 6.
3. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006 108 : 804 11.
4. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005 6 : 345 52.
5. Antony PA, Piccirillo CA, Akpinarli A et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005 174 : 2591 601.
6. Houghton AN, Gold JS, Blachere NE. Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 2001 13 : 134 40.
7. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006 29 : 233 40.
8. Shresta S, Heusel JW, Macivor DM et al. Granzyme B plays a critical role in cytotoxic lymphocyte-induced apoptosis. Immunol Rev 1995 146 : 211 21.
9. Bui JD, Uppaluri R, Hsieh CS, Schreiber RD. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res 2006 66 : 7301 9.
10. Hussein MR. Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity. Int J Exp Pathol 2006 87 : 163 76.
11. Hussein MR, Elsers DAH, Fadel SA, Omar AE. Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions. J Clin Pathol 2006 59 : 316 24.
12. + regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 2006 116 : 2423 33.
13. Chatenoud L, Bach J-F. Adaptive human regulatory T cells: myth or reality? J Clin Invest 2006 116 : 2325 7.
14. Lohr J, Knoechel B, Abbas AK. Regulatory T cells in the periphery. Immunol Rev 2006 212 : 149 62.
15. Valzasina B, Piconese S, Guiducci C et al. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res 2006 66 : 4488 95.
16. Wey S, Kryczek I, Zou W. Regulatory T-cell compartmentalization and trafficking. Blood 2006 108 : 426 31.
17. Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006 177 : 896 904.
18. Wang ZM, Hong J, Sun W et al. Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest 2006 116 : 2434 41.
19. + regulatory T cells. Nat Immunol 2003 4 : 330 6.
20. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003 299 : 1057 61.
21. Morgan ME, van Bilsen JH, Bakker AM et al. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum Immunol 2005 66 : 13 20.
22. Wang J, Ioan-Facsinay A, van der Voort EI et al. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007 37 : 129 38.
23. Ziegler SF. FOXP3: not just for regulatory T cells anymore. Eur J Immunol 2007 37 : 21 3.
24. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006 12 : 5423 34.
25. Viguier M, Lemaitre F, Verola O et al. Foxp3 expressing CD4+CD25 (high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004 173 : 1444 53.
26. Alvaro T, Lejeune M, Salvado MT et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005 11 : 1467 73.
27. Sato E, Olson SH, Ahn J et al. Intraepithelial tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. PNAS 2005 102 : 18538 43.
28. Wolf D, Wolf AM, Rumpold H et al. The expression of the regulatory T cell specific Forkhead Box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005 11 : 8326 31.
29. Appay V, Jandus C, Voelter V et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006 177 : 1670 8.
30. Grabenbauer GG, Lahmer G, Distel L et al. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006 12 : 3355 60.
31. Yang Z-Z, Novak AJ, Stenson MJ et al. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006 107 : 3639 46.
32. Keller JM, Maize JC. The clinical and histological differential diagnosis of malignant melanoma. Semin Oncol 1996 23 : 693 702.
33. Barnhill RL, Piepkorn M, Busam KJ, eds. Pathology of Melanocytic Nevi and Malignant Melanoma, 2nd edn. New York, NY : Springer-Verlag, 2004.
34. Clemente CG, Mihm MC Jr., Bufalino R et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996 77 : 1303 10.
35. Lyle S, Salhany KE, Elder DE. TIA-1 positive tumor-infiltrating lymphocytes in nevi and melanomas. Mod Pathol 2000 13 : 52 5.
36. Piepkorn M, Barnhill RL. Prognostic factors in cutaneous malignant melanoma. In : Pathology of Melanocytic Nevi and Malignant Melanoma (Barnhill RL, Piepkorn M, Busam KJ, eds 2nd edn. New York, NY : Springer-Verlag, 2004 372 94.
37. Perez J, Garcia PM, Bautista MJ et al. Immunohistochemical characterization of tumor cells and inflammatory infiltrate associated with cutaneous melanocytic tumors of Duroc and Iberian swine. Vet Pathol 2002 39 : 445 51.
38. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006 176 : 1582 7.
39. Xiao J, Chen HS. Biological functions of melanoma-associated antigens. World J Gastroenterol 2004 10 : 1849 53.
40. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004 22 : 1136 51.
41. Ghiringhelli F, Puig PE, Roux S et al. Tumor cells convert immature myeloid dendritic cells into TGF-ß-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005 202 : 919 29.
42. Hirahara K, Liu L, Clark RA et al. The majority of human peripheral blood CD4+ CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J Immunol 2006 177 : 4488 94.
43. Lizée G, Radyanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 2006 12 : 4794 803.
44. + suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 2003 26 : 85 93.
45. Cesana GC, DeRaffele G, Cohen S et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006 24 : 1169 77.
46. Robbins PF, Dudley ME, Wunderlich J et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004 173 : 7125 30.
47. Wing K, Fehervari Z, Sakaguchi S et al. Emerging possibilities in the development and function of regulatory T cells. Int Immunol 2006 18 : 991 1000.
48. Lurquin C, Lethe B, Plaen DC et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005 201 : 2449 57.
49. Ladanyi A, Somlai B, Gilde K et al. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 2004 10 : 521 30.
50. Gimotty PA, Van Belle P, Elder DE et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 2005 23 : 8048 56.
51. Nagore E, Oliver V, Botella-Estrada R et al. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. Melanoma Res 2005 15 : 169 77.